AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 6 - (NewsRx.com & NewsRx.net) -- Corpus leuteum support is an essential companion to GnRH antagonist stimulation.
"Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation. This randomized two-center study was performed to compare nonsupplemented luteal phase characteristics after three different strategies for inducing final oocyte maturation. Forty patients underwent ovarian stimulation using recombinant (r-) FSH ( 150 IU/day (d), fixed) combined with a GnRH antagonist (antide; 1 mg/d) during the late follicular phase," scientists in Netherlands reported.
"When at least one follicle above 18 mm was observed, patients were randomized to induce oocyte maturation by a single injection of either r- human hCG (250 microgram) (n=11), r- LH (1 mg) (n=13), or GnRH agonist (triptorelin; 0.2 mg) ( n=15)," explained N.G.M. Beckers and colleagues, Erasmus Medical Center, Department of Obstetrics and Gynecology.
"Retrieved oocytes were fertilized by either IVF or intracytoplasmatic sperm injection, depending on sperm quality. Embryo transfer was performed 3 - 4 days after oocyte retrieval. No luteal support was provided. Serum concentrations of FSH, LH, estradiol (E-2), progesterone (P), and hCG were assessed at fixed intervals during the follicular and luteal phase."
"The median duration of the luteal phase was 13, 10, and 9 d for the r-hCG, the r-LH, and the GnRH agonist group, respectively (p=0.005). The median area under the curve per day (from 4 d post randomization until the onset of menses) for LH was 0.50, 2.34, and 1.07 for the r-hCG, the r-LH, and the GnRH agonist group, respectively (p=0.001)," Becker's team reported.
...